-
Chairman Waxman’s Statement on FTC Report on Follow-on Biologic Drug Competition
Jun 10, 2009
-
Chairman Henry A. Waxman released a statement in response to a Federal Trade Commission report entitled, "Emerging Health Care Issues: Follow-on Biologic Drug Competition."
More
|
-
Energy & Commerce Committee Asks FDA to Reexamine Decision to Approve Medical Device
May 11, 2009
-
Chairman Henry A. Waxman, Subcommittee on Oversight and Investigations Chairman Bart Stupak, and Subcommittee on Health Chairman Frank Pallone, Jr., wrote to the Food and Drug Administration (FDA) requesting the agency to reexamine its decision in December to approve a medical device manufactured by ReGen Biologics, Inc. over the objection of FDA scientists.
More
|
-
Chairman Waxman’s Statement on FDA Nominations
Mar 14, 2009
-
Chairman Henry A. Waxman released a statement regarding the nominations of FDA Commissioner and Deputy Commissioner.
More
|
-
Health Leaders Introduce Legislation Reversing Supreme Court's Medical Device Decision
Mar 5, 2009
-
U.S. Reps. Frank Pallone, Jr. (D-NJ), Chairman of the Energy and Commerce Subcommittee on Health, and Henry A. Waxman (D-CA), Chairman of the Energy and Commerce Committee, today introduced legislation in the House that will reverse a U.S. Supreme Court decision that denies injured patients the ability to seek compensation for their injuries and gives medical device makers blanket immunity.
More
|
-
Waxman and Pallone Praise Supreme Court Decision Preserving Ability of Injured Patients to Seek Compensation
Mar 4, 2009
-
U.S. Reps. Henry A. Waxman (D-CA), Chairman of the House Energy and Commerce Committee, and Frank Pallone, Jr. (D-NJ), Chairman of the House Energy and Commerce Subcommittee on Health, praised the Supreme Court's decision today which preserved the right of patients injured by FDA-approved drugs to seek compensation through lawsuits against drug makers.
More
|
-
New GAO Report Finds Need for Additional FDA Oversight of Dietary Supplements
Mar 2, 2009
-
Rep. Henry A. Waxman (D-CA), Rep. John D. Dingell (D-MI), Rep. Bart Stupak (D-MI), and Sen. Dick Durbin (D-IL) released a new Government Accountability Office (GAO) report identifying several factors that limit FDA’s ability to protect consumers from unsafe dietary supplements.
More
|
-
Committee Investigates Doctor’s Dismissal from FDA Advisory Committee
Feb 27, 2009
-
Committee Chair Waxman and Subcommittee Chair Stupak wrote to the FDA and Eli Lilly regarding the removal of Dr. Sanjay Kaul from an FDA advisory committee on Prasugrel.
More
|
-
Chairmen Waxman and Stupak Request Study Data for Vytorin
Feb 19, 2009
-
Chairman Waxman and Subcommittee on Oversight and Investigations Chairman Stupak wrote to Schering-Plough and Merck, the companies developing Vytorin, to request further information regarding two studies on the drug.
More
|
-
Chairman Waxman Releases Internal FDA Documents Showing Career Staff Objected to Agency's New Stance on Preemption
Oct 29, 2008
-
According to a report released by Chairman Waxman, key FDA career officials strongly objected to Bush Administration drug labeling regulations that would preempt state liability lawsuits, asserting that the central justifications for the regulations were “false and misleading” and warning that the changes would deprive consumers of timely information about drug hazards.
More
|
-
Chairman Waxman Questions FDA Priorities
Sep 17, 2008
-
Chairman Waxman wrote to FDA Commissioner von Eschenbach to request answers to questions raised by internal FDA emails, which suggest that political appointees at the agency may be promoting industry priorities at the expense of FDA’s core public health mission.
More
|
|
Representative Henry A. Waxman 30th District of California
